Compare Dollar General Corp. (DG) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Nuwellis Inc — how do they compare? Dollar General Corp. trades at $124.27 (market cap $26.95B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Dollar General Corp. is far larger — about 12250× Nuwellis Inc's market cap, and Dollar General Corp. pays a 1.93% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Nuwellis Inc for 26 Days on average.
| DG | NUWE | |
|---|---|---|
Market Cap | $26.95B | $2.20M |
Volume | 1,654,929 | 121,544 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $146.65 |
52-Week Low | $95.94 | $0.68 |
Typical Hold Time | 59 Days | 26 Days |
Enterprise Value | $41.13B | -$1.52M |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $124.27, up 0.82% on the day, with a neutral technical signal and bearish moving average trend. The stock shows strong valuation metrics with a P/E of 15.86 and P/S of 0.62, while recent earnings have consistently beaten estimates. Revenue growth is steady, reaching $40.61 billion in 2025, though net income margin has compressed to 2.77%. Positive news includes tariff refunds boosting margins and expansion of same-day delivery via Instacart.
The outlook is cautiously optimistic, supported by analyst consensus price target of $137.27 (10.5% upside) and a 55.77% buy rating. Key opportunities include margin recovery initiatives and digital growth, while risks involve competitive pressures and consumer spending volatility. The stock presents a value opportunity with upside potential if execution improves.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
